Testing for BRCA mutations linked to breast and ovarian cancers could become easier and more accessible with the help of artificial intelligence, potentially allowing earlier treatment.
Proscia, an AI-enabled pathology solutions software company, has announced the launch of Concentriq Embeddings and the Proscia AI Toolkit, hoping to accelerate precision medicine R&D.
Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumour histopathology images.